| Overall WMS-R memory | Lysolecithin showed no advantage in overall memory over eight weeks.Overall WMS-R memory: 100.8→110.7 versus 108.5→115.2; no significant between-group difference. | 2/4 LowPrecision of the estimate: 45 analysed and no CI of the effect. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Marked baseline memory imbalance complicates assessment of changes. | 11 trialEffects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial ↗ | 46 adults aged 40–74, analysis 23 and 22 | - Effects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial ↗
|
|---|
| Primary Spatial Span / Monkey Ladder | Citicoline showed no advantage in the primary spatial memory test over 12 weeks.Spatial Span: 4.65→4.90 versus 4.75→4.67; no between-group advantage in the primary outcome. | 2/4 LowPrecision of the estimate: One RCT, CI of the contrast not provided in the extraction. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Industry funding and incomplete quantitative reporting of the primary contrast. | 11 trialCiticoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗ | 100 adults aged 50–85 with age-related memory complaints, 99 completed | - Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗
|
|---|
| Secondary Paired Associates, episodic memory | In the secondary episodic memory test, the score improved by 0.15 versus 0.06 points with placebo.Paired Associates change +0.15 versus +0.06; p=0.0025 after correction for multiple comparisons. | 1/4 Very lowPrecision of the estimate: One RCT without an exact contrast CI in the extraction. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The laboratory test does not measure preservation of everyday function. Possible publication bias: No data for a separate downgrade. Study methods: Secondary result in a test battery. | 11 trialCiticoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗ | 100 adults aged 50–85 with age-related memory complaints, 99 completed | - Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗
|
|---|
| Time to exhaustion | Time to exhaustion did not differ significantly in the two cycling exercise protocols.Time to exhaustion was similar in both cycling protocols. | 2/4 LowPrecision of the estimate: Two groups of 10 and CI not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Available reporting insufficient to assess concealment and analysis. | 11 trialEffect of choline supplementation on fatigue in trained cyclists ↗ | 20 trained men aged 23–29, 10 each at 150% and 70% VO₂max | - Effect of choline supplementation on fatigue in trained cyclists ↗
|
|---|
| Work performed | Work performed did not differ significantly in the two cycling exercise protocols.Work performed was similar in both cycling protocols. | 2/4 LowPrecision of the estimate: Two groups of 10 and CI not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: The comparison directly answers the stated study question. Possible publication bias: No data for a separate downgrade. Study methods: Available reporting insufficient to assess concealment and analysis. | 11 trialEffect of choline supplementation on fatigue in trained cyclists ↗ | 20 trained men aged 23–29, 10 each at 150% and 70% VO₂max | - Effect of choline supplementation on fatigue in trained cyclists ↗
|
|---|
| Running to fatigue after the march | No advantage in running to exhaustion after the march was found.No significant advantage in running to exhaustion was reported. | 1/4 Very lowPrecision of the estimate: 14 participants, CI not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A specific heavily loaded march. Possible publication bias: No data for a separate downgrade. Study methods: Full dosing regimen and analysis unavailable in the abstract. | 11 trialThe effects of choline supplementation on physical performance ↗ | 14 participants, 4 h walking at 5.6 km/h with a 34.1 kg load, 3% incline | - The effects of choline supplementation on physical performance ↗
|
|---|
| Squats after the march | No advantage in squats after the march was found.No significant advantage in squats was reported. | 1/4 Very lowPrecision of the estimate: 14 participants, CI not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A specific heavily loaded march. Possible publication bias: No data for a separate downgrade. Study methods: Full dosing regimen and analysis unavailable in the abstract. | 11 trialThe effects of choline supplementation on physical performance ↗ | 14 participants, 4 h walking at 5.6 km/h with a 34.1 kg load, 3% incline | - The effects of choline supplementation on physical performance ↗
|
|---|
| Upper-body isometric strength | No difference in upper-body isometric strength was found between the four groups.No difference in upper-body isometric strength was found between the four groups, p=0.743. | 1/4 Very lowPrecision of the estimate: 12 per group, large SDs and no CIs for pairwise contrasts. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A laboratory measure in a narrow group of young men. Possible publication bias: No data for a separate downgrade. Study methods: Several tests and comparisons, small group for each dose. | 11 trialEvaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance ↗ | 48 young men, four groups of 12 | - Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance ↗
|
|---|
| Lower-body isometric strength | No advantage of α-GPC over placebo in lower-body isometric strength was found; caffeine was assessed separately.In the follow-up comparison of lower-body isometric strength, caffeine differed from placebo, but α-GPC did not. | 1/4 Very lowPrecision of the estimate: 12 per group, large SDs and no CIs for pairwise contrasts. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A laboratory measure in a narrow group of young men. Possible publication bias: No data for a separate downgrade. Study methods: Several tests and comparisons, small group for each dose. | 11 trialEvaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance ↗ | 48 young men, four groups of 12 | - Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance ↗
|
|---|
| Psychomotor vigilance | No between-group difference in psychomotor vigilance was found.No between-group difference in psychomotor vigilance was found, p>0.5. | 1/4 Very lowPrecision of the estimate: 12 per group, large SDs and no CIs for pairwise contrasts. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: A laboratory measure in a narrow group of young men. Possible publication bias: No data for a separate downgrade. Study methods: Several tests and comparisons, small group for each dose. | 11 trialEvaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance ↗ | 48 young men, four groups of 12 | - Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance ↗
|
|---|
| infant memory | Infant memory at 10 and 12 months showed no advantage over placebo.Infant short-term and episodic memory at 10 and 12 months did not differ between groups; 99 assessed. | 1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias | 11 trialPhosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial ↗ | 140 pregnant women randomised, 99 infants assessed alongside moderate dietary choline intake (about 360 mg/day) | - Phosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| infant language development | Infant language development at 10 and 12 months showed no advantage over placebo.Infant language development at 10 and 12 months did not differ between groups; 99 assessed. | 1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias | 11 trialPhosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial ↗ | 140 pregnant women randomised, 99 infants assessed alongside moderate dietary choline intake (about 360 mg/day) | - Phosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| infant overall development | Infant overall development at 10 and 12 months showed no advantage over placebo.Infant overall development at 10 and 12 months did not differ between groups; 99 assessed. | 1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias | 11 trialPhosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial ↗ | 140 pregnant women randomised, 99 infants assessed alongside moderate dietary choline intake (about 360 mg/day) | - Phosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| CBCL social withdrawal, second primary outcome | Parents reported multiple or persistent signs of social withdrawal less often in children in the phosphatidylcholine group.In 142 children, parent-reported CBCL identified fewer multiple or persistent social withdrawal problems in the supplement group. | 1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias | 11 trialPrenatal Maternal Phosphatidylcholine and Children's Behavior and Cognition through 4 Years of Age: Randomized Clinical Trial ↗ | 206 pregnant women randomised, 142 children with parent ratings | - Prenatal Maternal Phosphatidylcholine and Children's Behavior and Cognition through 4 Years of Age: Randomized Clinical Trial ↗
|
|---|
| overall WPPSI-IV IQ | Children's secondary overall IQ score was on average 7.78 points higher than in the placebo group.Secondary overall IQ: mean difference +7.78 points, 95% CI +1.88…+13.7; data for 103 children (54 and 49). | 1/4 Very lowPrecision of the estimate: small sample, attrition or wide interval Consistency of results: no substantial grounds for downgrading established. Applicability to the stated group: indirect applicability to the general population, form or clinical outcome Possible publication bias: no substantial grounds for downgrading established. Study methods: study method and possible bias | 11 trialPrenatal Maternal Phosphatidylcholine and Children's Behavior and Cognition through 4 Years of Age: Randomized Clinical Trial ↗ | children of a subset of the 206 randomised pregnant women; secondary outcome | - Prenatal Maternal Phosphatidylcholine and Children's Behavior and Cognition through 4 Years of Age: Randomized Clinical Trial ↗
|
|---|
| Acute mood | Self-rated mood after a single dose did not differ between groups.Self-rated mood 6.46±1.09 versus 6.48±1.00, p=0.889. | 1/4 Very lowPrecision of the estimate: Small sample, exact CI of the contrast not provided. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: Single dose and brief self-rating. Possible publication bias: No data for a separate downgrade. Study methods: Analysis df=27 with 37 experiment completers, exact set incomplete. | 11 trialNo Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗ | Healthy adults aged 18–29, 40 started experiment 3, 37 completed | - No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗
|
|---|
| Acute arousal | Self-rated arousal after a single dose did not differ between groups.Self-rated arousal 4.62±1.62 versus 4.95±1.47, p=0.171. | 1/4 Very lowPrecision of the estimate: Small sample, exact CI of the contrast not provided. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: Single dose and brief self-rating. Possible publication bias: No data for a separate downgrade. Study methods: Analysis df=27 with 37 experiment completers, exact set incomplete. | 11 trialNo Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗ | Healthy adults aged 18–29, 40 started experiment 3, 37 completed | - No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults ↗
|
|---|
| Self-rated sleep | No advantage in self-rated sleep was found over eight weeks.Self-rated sleep: baseline 80.8 versus 76.5, at week 8 80.7 versus 77.5; no between-group advantage. | 1/4 Very lowPrecision of the estimate: 45 analysed, CI of the between-group effect not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: Sample without marked sleep disorders, clinical anxiety not studied. Possible publication bias: No data for a separate downgrade. Study methods: Secondary self-ratings, marked baseline imbalance for calmness. | 11 trialEffects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial ↗ | 46 adults aged 40–74, analysis 23 and 22 | - Effects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial ↗
|
|---|
| Self-rated calmness | No advantage in self-rated calmness was found by the end of week eight.Self-rated calmness: 73.7→82.6 versus 85.3→85.5; no final between-group advantage. | 1/4 Very lowPrecision of the estimate: 45 analysed, CI of the between-group effect not extracted. Consistency of results: No comparable independent series for this outcome and comparison. Applicability to the stated group: Sample without marked sleep disorders, clinical anxiety not studied. Possible publication bias: No data for a separate downgrade. Study methods: Secondary self-ratings, marked baseline imbalance for calmness. | 11 trialEffects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial ↗ | 46 adults aged 40–74, analysis 23 and 22 | - Effects of an 8-week intake of lysolecithin on cognitive function and concentrations of blood choline and lysophosphatidylcholine: a randomized, double-blinded, placebo-controlled trial ↗
|
|---|
| Attention problems in children after prenatal intake | The primary attention-scale analysis found no advantage.No significant reduction in attention problems was found in the primary comparison; the exact CI is absent from the abstract. | 1/4 Very lowrisk_of_bias: 64 of 206 randomised absent from the CBCL set, possible selection. inconsistency: No comparable independent series for this outcome and comparison. indirectness: A specific prenatal regimen and parent scale, without transfer to a diagnosis. imprecision: No exact CI, 142 children assessed. publication_bias: No data for a separate downgrade. | 11 trialPrenatal Maternal Phosphatidylcholine and Children's Behavior and Cognition through 4 Years of Age: Randomized Clinical Trial ↗ | 206 randomised pregnant women, 142 children assessed by CBCL at 18 months–4 years | - Prenatal Maternal Phosphatidylcholine and Children's Behavior and Cognition through 4 Years of Age: Randomized Clinical Trial ↗
|
|---|
| Jump power: comparison of two α-GPC doses | A difference in power was found between two doses.Changes +151.77±300.54, −143.83±344.03 and +31.29±277.29 N·m/s for 250, 500 mg and placebo, respectively. p<0.05 only for 250 versus 500 mg in the stated post hoc comparison. | 1/4 Very lowrisk_of_bias: Several tests and comparisons, small group for each dose. inconsistency: No comparable independent series for this outcome and comparison. indirectness: A laboratory measure in a narrow group of young men. imprecision: 12 per group, large SDs and no CIs for pairwise contrasts. publication_bias: No data for a separate downgrade. | 11 trialEvaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance ↗ | 48 young men, four groups of 12 | - Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance ↗
|
|---|